Vol. 3 No. 5 (2025), Articles
Vol. 3 No. 5 (2025)

NOVEL BIOMARKERS IN EARLY DETECTION OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

Articles
Published 2025-06-23
Nuralieva Dilbar
Student of the Termez branch of the Tashkent medical academy
PDF
DOI

Keywords

HFpEF, heart failure, galectin-3, sST2, GDF-15, biomarkers, preserved ejection fraction, early diagnosis

How to Cite

NOVEL BIOMARKERS IN EARLY DETECTION OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF). (2025). "Conference on Universal Science Research 2023", 3(5), 32-37. https://universalpublishings.com/index.php/cusr/article/view/12826
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Heart Failure with Preserved Ejection Fraction (HFpEF) represents a complex and increasingly prevalent form of heart failure characterized by typical heart failure symptoms despite a normal or near-normal left ventricular ejection fraction. Unlike Heart Failure with Reduced Ejection Fraction (HFrEF), HFpEF remains difficult to diagnose in its early stages due to nonspecific clinical presentation and the limitations of conventional diagnostic tools. 

PDF
DOI

References

1. Anand, I. S., & Rector, T. S. (2012). Prognostic value of soluble ST2 in heart failure: findings from the HF-ACTION study. Journal of the American College of Cardiology, 60(9), 722–730. https://doi.org/10.1016/j.jacc.2012.04.032

2. Gaggin, H. K., & Januzzi, J. L. (2013). Biomarkers and diagnostics in heart failure. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1832(12), 2442–2450. https://doi.org/10.1016/j.bbadis.2013.01.010

3. van Kimmenade, R. R. J., et al. (2006). Usefulness of BioMarkers in Diagnosing HFpEF. American Journal of Cardiology, 97(10), 1531–1537. https://doi.org/10.1016/j.amjcard.2005.12.048

4. Sharma, K., et al. (2018). Randomized evaluation of galectin-3 inhibition in HFpEF. JACC: Heart Failure, 6(7), 553–562. https://doi.org/10.1016/j.jchf.2018.02.015

5. Maisel, A., et al. (2011). Soluble ST2 testing in HF: A marker for risk stratification. Journal of the American College of Cardiology, 58(25), 2635–2643. https://doi.org/10.1016/j.jacc.2011.07.054

6. Daniels, L. B., & Clopton, P. (2014). Use of GDF-15 for early detection of heart failure. Clinical Chemistry, 60(9), 1222–1230. https://doi.org/10.1373/clinchem.2014.224873

7. Bayes-Genis, A., et al. (2015). Neprilysin and biomarkers in heart failure. Current Heart Failure Reports, 12, 47–53. https://doi.org/10.1007/s11897-014-0235-y

8. Pieske, B., et al. (2019). How to diagnose HFpEF: A stepwise approach. European Heart Journal, 40(44), 3641–3653. https://doi.org/10.1093/eurheartj/ehz597

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.